Market research
LAB.F Laboratory Corporation of America Holdings
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 17B
- P/E ratio
- 45.48
- Analyst target
- 334.29
- Dividend yield
- 1.4%
- Beta
- 1.01
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- US50540R4092
- Market cap
- 17B
- P/E ratio
- 45.48
- Analyst target
- 334.29
- Dividend yield
- 1.4%
- Beta
- 1.01
About
About Laboratory Corporation of America Holdings
Labcorp Holdings Inc. operates as a laboratory services company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. In addition, the company offers online and mobile applications that enable patients to check test results; online applications for providers, MCOs, and accountable care organizations; and drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical la
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the LAB.F discussion.
5 years, 4 months ago
Laboratory Corporation of America Holdings is currently in a long term uptrend where the price is trading 22.0% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.8.
Laboratory Corporation of America Holdings's total revenue rose by 52.0% to $4B since the same quarter in the previous year.
Its net income has increased by 313.2% to $938M since the same quarter in the previous year.
Finally, its free cash flow grew by 52.9% to $675M since the same quarter in the previous year.
Based on the above factors, Laboratory Corporation of America Holdings gets an overall score of 5/5.